Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Bladder Cancer

Free Subscription 17.11.2025 1 Abdom Radiol (NY) 2 Adv Sci (Weinh) 1 Am J Surg Pathol 2 BJU Int 1 Bladder Cancer 1 BMC Cancer 1 BMC Microbiol 3 Can J Urol 1 Cancer Cell Int 1 Cancer Immunol Immunother 1 Cancer Lett 4 Cancers (Basel) 1 Cir Pediatr 1 Clin Exp Metastasis 1 Clin Genitourin Cancer 1 Clin Nutr ESPEN 1 Comput Methods Biomech Biomed Engin 1 Cureus 1 Discov Oncol 1 Ecotoxicol Environ Saf 1 Eur J Med Res 1 Eur Urol Oncol 1 Front Oncol 1 Int J Mol Sci 3 Int J Surg 1 Int Urol Nephrol 1 J Biochem Mol Toxicol 1 J Clin Med 1 J Oncol 1 J Robot Surg 1 J Transl Med 1 J Urol 1 J Vasc Access 1 Jpn J Clin Oncol 1 Mol Oncol 1 Nature 1 Oncol Ther 2 Sci Rep 6 Transl Androl Urol 1 Urol Int 6 Urol Oncol 1 Urol Pract 1 Urologia 2 World J Urol 1 Zhonghua Wai Ke Za Zhi

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Abdom Radiol (NY)

1. ZHANG X, Guo J, Wang L, Ma Y, et al
   Recurrence risk prediction for non-muscle-invasive bladder urothelial carcinoma using diffusion and clinicopathology features.
   Abdom Radiol (NY). 2025;50:5903-5914.
   PubMed         Abstract available
   
   

   
   Adv Sci (Weinh)

2. ZHAO B, Huang Y, Shi J, Zhou X, et al
   XPC Deficiency Activate Cisplatin-Mediated Autophagy in Bladder Cancer by Limiting Novel PHRF1-Mediated Ubiquitination of the p53 Protein.
   Adv Sci (Weinh). 2025 Nov 11:e17563. doi: 10.1002/advs.202517563.
   PubMed         Abstract available
   
   
3. HUANG Y, Chen C, Su M, Li D, et al
   MCUB Inhibits PRKN-Dependent Mitophagic Degradation of PD-L1 to Promote Immune Evasion in Bladder Cancer.
   Adv Sci (Weinh). 2025 Nov 12:e14764. doi: 10.1002/advs.202514764.
   PubMed         Abstract available
   
   

   
   Am J Surg Pathol

4. DOWNES MR, Lopez-Beltran A, Contieri R, Hansel DE, et al
   International Society of Urological Pathology Consensus Meeting 2024: Working Group 2 Preneoplastic and Precursor Lesions of the Urinary Bladder.
   Am J Surg Pathol. 2025;49:e46-e57.
   PubMed         Abstract available
   
   

   
   BJU Int

5. ROBERTS IA, Cumberbatch MG, Catto JWF
   Renal, bladder and prostate cancer surgery outcomes with respect to team familiarity.
   BJU Int. 2025 Sep 4. doi: 10.1111/bju.16920.
   PubMed         Abstract available
   
   
6. PAYNTER JA, Doherty Z, Qin KR, Pilcher D, et al
   Outcomes after cystectomy in Australian rural and metropolitan hospitals by intensive care admissions.
   BJU Int. 2025;136 Suppl 2.
   PubMed         Abstract available
   
   

   
   Bladder Cancer

7. MALSHY K, Messing EM
   Can urinary tumor DNA be used to assess the risk of recurrence in patients with non-muscle invasive bladder cancer?
   Bladder Cancer. 2025;11:23523735251395843.
   PubMed        
   
   

   
   BMC Cancer

8. LEE SY, Lee YH, Kim TM, Ha US, et al
   TGF-beta signaling and tumor microenvironment dynamics in bladder cancer progression post-BCG therapy: a longitudinal single-nucleus RNA-seq study.
   BMC Cancer. 2025;25:1735.
   PubMed         Abstract available
   
   

   
   BMC Microbiol

9. XIE H, Dong C, Li Y, Guo J, et al
   XGBoost-based urinary microbial signatures enable non-invasive diagnosis and prognosis for urothelial carcinoma.
   BMC Microbiol. 2025;25:732.
   PubMed         Abstract available
   
   

   
   Can J Urol

10. LYU J, Yue R, Zhu Y, Tian Y, et al
    Association of urinary tract infection and low albumin/globulin ratio with chemoresistance to gemcitabine-cisplatin in advanced urothelial carcinoma.
    Can J Urol. 2025;32:411-422.
    PubMed         Abstract available
    
    
11. HOFFMAN A, Kochavi E, Amiel GE
    Cryotherapy for non-muscle invasive bladder cancer-preliminary results in an animal model.
    Can J Urol. 2025;32:423-432.
    PubMed         Abstract available
    
    
12. ZHANG L, Cao L, Huang L, Wang J, et al
    Associations of systemic immune-inflammation index, product of platelet, and neutrophil count, with the pathological grade of bladder cancer.
    Can J Urol. 2025;32:457-468.
    PubMed         Abstract available
    
    

    
    Cancer Cell Int

13. SHEN H, Zheng F, Tang X, Ma Z, et al
    Constructing a bladder cancer prognostic model related to exosome using machine learning and identifying THBS1 as a potential target.
    Cancer Cell Int. 2025;25:392.
    PubMed         Abstract available
    
    

    
    Cancer Immunol Immunother

14. VARADI M, Horvath O, Soos E, Csizmarik A, et al
    Combining molecular patterns and clinical data for better immune checkpoint inhibitor prediction in metastatic urothelial carcinoma.
    Cancer Immunol Immunother. 2025;74:370.
    PubMed         Abstract available
    
    

    
    Cancer Lett

15. HAMMOUDA K, Tokuyama N, Corredor G, Pathak T, et al
    AI-informed computational pathology classifier predicts outcomes across treatment modalities in muscle-invasive urothelial carcinoma.
    Cancer Lett. 2025;634:218059.
    PubMed         Abstract available
    
    

    
    Cancers (Basel)

16. GUSZCZ T, Lukaszewski Z, Gorodkiewicz E, Hermanowicz A, et al
    Potential of Proteases in the Diagnosis of Bladder Cancer.
    Cancers (Basel). 2025;17:3460.
    PubMed         Abstract available
    
    
17. YANG Z, Song F, Zhong J
    Urinary Biomarkers in Bladder Cancer: FDA-Approved Tests and Emerging Tools for Diagnosis and Surveillance.
    Cancers (Basel). 2025;17:3425.
    PubMed         Abstract available
    
    
18. GABRIEL PE, Horowitz A, Guerrero-Ramos F, Soria F, et al
    Therapeutic Intensification Based on Immune Checkpoint Inhibitors in Non-Muscle Invasive Bladder Cancer: State of the Art and Future Perspectives.
    Cancers (Basel). 2025;17:3555.
    PubMed         Abstract available
    
    
19. NINOMIYA S, Ishiguro Y, Hasumi H, Jikuya R, et al
    The Role of FGFR3 in the Progression of Bladder Cancer.
    Cancers (Basel). 2025;17:3588.
    PubMed         Abstract available
    
    

    
    Cir Pediatr

20. PEREZ COSTOYA C, Granell Suarez C, Alvarez Munoz V, Gomez Farpon A, et al
    Management of nephrogenic adenoma in pediatric patients with multiple urological interventions.
    Cir Pediatr. 2025;38:163-166.
    PubMed         Abstract available
    
    

    
    Clin Exp Metastasis

21. ZOU XC, Wang B, Yu ZJ, Chao HC, et al
    A radiomics-driven machine learning model for predicting bladder cancer prognosis identifies genes associated with radiomic features.
    Clin Exp Metastasis. 2025;42:63.
    PubMed        
    
    

    
    Clin Genitourin Cancer

22. DAVIES-TEYE BB, Seo D, Johnson A, Stuart J, et al
    Trends in Treatment Patterns and Outcomes Among Patients Diagnosed With Nonmuscle-Invasive Bladder Cancer in the United States.
    Clin Genitourin Cancer. 2025 Aug 29:102424. doi: 10.1016/j.clgc.2025.102424.
    PubMed         Abstract available
    
    

    
    Clin Nutr ESPEN

23. LETH KIRSTEN SL, Loff AM, Christensen SH, Munk T, et al
    Low albumin-corrected plasma zinc is common among patients with bladder cancer undergoing cystectomy.
    Clin Nutr ESPEN. 2025 Nov 11:S2405-4577(25)02999.
    PubMed         Abstract available
    
    

    
    Comput Methods Biomech Biomed Engin

24. SHAO Y, Yu Q, Zhu J, Wang X, et al
    Construction and mechanistic exploration of a ferroptosis related gene based prognostic model for cisplatin resistance in bladder cancer.
    Comput Methods Biomech Biomed Engin. 2025.
    PubMed         Abstract available
    
    

    
    Cureus

25. TANTRAY MA, Khan TA, Malik SA, Para SA, et al
    Predicting Histopathological Outcomes from Cystoscopic Findings in Newly Diagnosed Bladder Cancer: A Prospective Observational Study.
    Cureus. 2025;17:e94251.
    PubMed         Abstract available
    
    

    
    Discov Oncol

26. MAMDOUH S, Aboushousha T, Hemida E, El-Araby RE, et al
    Role of microRNA-183 based theranostics through targeting TPM1 in bladder cancer.
    Discov Oncol. 2025;16:2100.
    PubMed         Abstract available
    
    

    
    Ecotoxicol Environ Saf

27. ZHU T, Luo W, Zhang Y, Liang Z, et al
    Methylparaben and propylparaben promote bladder cancer invasion via MMP2 and PPARG modulation.
    Ecotoxicol Environ Saf. 2025;306:119383.
    PubMed         Abstract available
    
    

    
    Eur J Med Res

28. ZHOU H, Lin S, Sun C, Ge Z, et al
    Evaluation of the diagnostic performance of YiDiXie tests in urothelial carcinoma.
    Eur J Med Res. 2025;30:1113.
    PubMed         Abstract available
    
    

    
    Eur Urol Oncol

29. WEITZNER AS, Grutman AJ, Arbuiso A, Cheaib J, et al
    Gender-based Differences in Psychosocial Well-being Among Bladder Cancer Survivors.
    Eur Urol Oncol. 2025 Nov 11:S2588-9311(25)00239.
    PubMed         Abstract available
    
    

    
    Front Oncol

30. BAI J, Huang Y, Chen B, Ran B, et al
    Prognostic value of the systemic immune-inflammation index in bladder cancer: an update evidence-based analysis.
    Front Oncol. 2025;15:1707657.
    PubMed         Abstract available
    
    

    
    Int J Mol Sci

31. BUTT UA, De Biase D
    The Urinary Microbiota and the Gut-Bladder Axis in Bladder Cancer.
    Int J Mol Sci. 2025;26:10558.
    PubMed         Abstract available
    
    

    
    Int J Surg

32. LUO X, Zhang Y, Wang W, Xiong Y, et al
    Analysis of global burden of male kidney, prostate, and bladder cancers: comparative study of relevant risk factors from 1990 to 2019.
    Int J Surg. 2025 Nov 10. doi: 10.1097/JS9.0000000000003783.
    PubMed        
    
    
33. REN JW, Bai YJ, Han P
    Cancer-specific chronotherapy and insights into non-muscle-invasive bladder cancer: a correspondence.
    Int J Surg. 2025 Nov 12. doi: 10.1097/JS9.0000000000003998.
    PubMed        
    
    
34. GAO L, Chen J, Shang K, Wang G, et al
    MicroRNAs in bladder cancer: biogenesis, function, and therapeutic strategies.
    Int J Surg. 2025 Nov 13. doi: 10.1097/JS9.0000000000003947.
    PubMed         Abstract available
    
    

    
    Int Urol Nephrol

35. RAJA IYUB MJ, Prabhakar P, Sakthivel DK, Chandrasekaran A, et al
    Metastatic non-muscle invasive bladder cancer: histology-specific metastatic patterns and survival in a national cancer database analysis.
    Int Urol Nephrol. 2025 Nov 11. doi: 10.1007/s11255-025-04907.
    PubMed         Abstract available
    
    

    
    J Biochem Mol Toxicol

36. MOHTADI S, Molavinia S, Shariati S, Mahdavinia M, et al
    Exploring the Effectiveness of Sitagliptin to Enhance Cisplatin Chemosensitivity in HTB-9 Bladder Cancer Cells.
    J Biochem Mol Toxicol. 2025;39:e70584.
    PubMed         Abstract available
    
    

    
    J Clin Med

37. PATEL K, Radcliffe R
    Evaluating the Readability and Quality of Bladder Cancer Information from AI Chatbots: A Comparative Study Between ChatGPT, Google Gemini, Grok, Claude and DeepSeek.
    J Clin Med. 2025;14:7804.
    PubMed         Abstract available
    
    

    
    J Oncol

38. 
    Correction to "M2 Tumor Associate Macrophage- (TAM-) Derived lncRNA HISLA Promotes EMT Potential in Bladder Cancer".
    J Oncol. 2025;2025:9754691.
    PubMed         Abstract available
    
    

    
    J Robot Surg

39. KOHLER J, Buck L, Hugelmann K, Incesu RB, et al
    Expanding the role of robotic surgery: Non-inferiority of robot-assisted radical cystectomy in overweight patients with bladder cancer.
    J Robot Surg. 2025;20:9.
    PubMed         Abstract available
    
    

    
    J Transl Med

40. DING X, Zhang E, Huang Z, Li X, et al
    Glutamine metabolism reprogramming promotes bladder cancer progression via PYCR1: a multi-omics and functional validation study.
    J Transl Med. 2025;23:1277.
    PubMed         Abstract available
    
    

    
    J Urol

41. FENG Y, Zhou S, Huang S, Yu Z, et al
    Letter: Prolonged Progression-Free Survival, Disease-Free Survival and Cystectomy Avoidance With IL-15 Receptor Lymphocyte-Stimulating Agent NAI Plus Bacillus Calmette-Guerin in Bacillus Calmette-Guerin-Unresponsive Papillary-Only Nonmuscle-Invasive B
    J Urol. 2025 Nov 13:101097JU0000000000004792. doi: 10.1097/JU.0000000000004792.
    PubMed        
    
    

    
    J Vasc Access

42. LI S, Liu Y, Wang B, Ning Y, et al
    PICC management for bladder tumor patient with toxic epidermal necrolysis: A crisis intervention case report.
    J Vasc Access. 2025;26:2122-2127.
    PubMed         Abstract available
    
    

    
    Jpn J Clin Oncol

43. IKEHATA Y, Nishiyama N, Ishida S, Kitamura H, et al
    Evaluation of the utility of molecular subtype classification by immunohistochemistry in bladder cancer undergoing radical cystectomy: a retrospective cohort study.
    Jpn J Clin Oncol. 2025 Nov 5:hyaf167. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Mol Oncol

44. SCHMITZ J, Bartkowiak AL, Rose M, Kolks N, et al
    Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107.
    Mol Oncol. 2025 Nov 11. doi: 10.1002/1878-0261.70148.
    PubMed         Abstract available
    
    

    
    Nature

45. CALVET F, Blanco Martinez-Illescas R, Muinos F, Tretiakova M, et al
    Sex and smoking bias in the selection of somatic mutations in human bladder.
    Nature. 2025;647:436-444.
    PubMed         Abstract available
    
    

    
    Oncol Ther

46. GRIEBSCH I, Shrestha S, Lotan Y, Ng CF, et al
    The Impact of Intravesical Instillations on Quality of Life in Patients with Non-Muscle-Invasive Bladder Cancer: A Systematic Review.
    Oncol Ther. 2025 Nov 13. doi: 10.1007/s40487-025-00375.
    PubMed         Abstract available
    
    

    
    Sci Rep

47. ZHAO S, Li R, Tian T, Zhang J, et al
    Single-cell RNA sequencing identifies potential critical prognostic biomarkers in bladder carcinoma.
    Sci Rep. 2025;15:39105.
    PubMed         Abstract available
    
    
48. ZHANG B, Yao Z, Zhou Z, Zhang Y, et al
    The serum platelet-to-lymphocyte ratio as a predictor of outcomes in bladder cancer patients: an updated meta-analysis.
    Sci Rep. 2025;15:39502.
    PubMed         Abstract available
    
    

    
    Transl Androl Urol

49. YU L, Gao S, Li D, Chen X, et al
    Identification of molecular subtypes and prognostic risk model of glucocorticoid-related lncRNAs in bladder cancer to evaluate prognosis and immunological characteristics.
    Transl Androl Urol. 2025;14:3277-3297.
    PubMed         Abstract available
    
    
50. HUANG X, Sun Y, Tong H, Zhu J, et al
    Ursolic acid sensitizes bladder cancer to gemcitabine chemotherapy by concurrently targeting PI3K/AKT and JNK pathways.
    Transl Androl Urol. 2025;14:2902-2916.
    PubMed         Abstract available
    
    
51. DOSHI H, Geynisman DM
    Checkmate 274: expanding treatment options for muscle-invasive bladder cancer.
    Transl Androl Urol. 2025;14:2786-2791.
    PubMed        
    
    
52. LIU T, Yao Y, Huang J, Ji J, et al
    A log odds of positive lymph nodes (LODDS)-based nomogram for survival prediction in elderly bladder cancer patients after radical cystectomy: development and validation using SEER and Chinese cohorts.
    Transl Androl Urol. 2025;14:2873-2884.
    PubMed         Abstract available
    
    
53. DAI F, He Y, Huang X, Lin K, et al
    Integrating transcriptomics, single-cell omics, and deep learning-based histopathological features to identify OLFML3 in bladder cancer.
    Transl Androl Urol. 2025;14:3097-3113.
    PubMed         Abstract available
    
    
54. ALBAKR A, Narayan VM, Tyson M, Shoskes D, et al
    Pharmacotherapy for bladder spasm and irritative lower urinary tract symptoms associated with intravesical therapy for bladder cancer: a review of available evidence.
    Transl Androl Urol. 2025;14:3402-3412.
    PubMed         Abstract available
    
    

    
    Urol Int

55. QIN N, Chen L, Guo J, Wang J, et al
    Bladder Cancer Burden Across Global, Regional, and National Levels (1990-2021): Associations with Sociodemographic Index, Multidimensional Analyses, and Projections to 2036.
    Urol Int. 2025 Nov 11:1-27. doi: 10.1159/000548815.
    PubMed         Abstract available
    
    

    
    Urol Oncol

56. RAPP DE, Zillioux J
    Radical cystectomy in the female patient: The pelvic floor, sexual function, and patient/provider education.
    Urol Oncol. 2025;43:680-684.
    PubMed         Abstract available
    
    
57. KRISCHAK MK, Bank M, Daignault-Newton S, Semerjian AM, et al
    Assessing the sex-based enrollment gap in urologic oncology clinical trials.
    Urol Oncol. 2025;43:709.
    PubMed         Abstract available
    
    
58. EBNER B, Hirsch J, Holz A, Volz Y, et al
    Association of interleukin-6 serum levels with local tumor stage and lymph node metastasis of urothelial carcinoma.
    Urol Oncol. 2025;43:693.
    PubMed         Abstract available
    
    
59. NATIV O, Sadiq S, Williams A, Reid G, et al
    Utilization of intravesical chemotherapy following TURBT: A pre-implementation analysis of American College of Surgeon Commission on Cancer GU quality measures.
    Urol Oncol. 2025;43:696.
    PubMed         Abstract available
    
    
60. TOMITA Y, Ye DW, Fujii A, Takeuchi N, et al
    Nivolumab plus gemcitabine-cisplatin for previously untreated unresectable or metastatic urothelial carcinoma: an Asian subgroup analysis from the global phase 3 CheckMate 901 trial.
    Urol Oncol. 2025;43:696.
    PubMed         Abstract available
    
    
61. CHUNG R, Montanaro F, Croll B, Correa A, et al
    Time to change the template: An oncologic appraisal of organ sparing cystectomy in the female patient.
    Urol Oncol. 2025;43:685-692.
    PubMed         Abstract available
    
    

    
    Urol Pract

62. PEYTON CC, Kates M, Nadkarni A, Dhanda R, et al
    Patient-reported outcomes following UGN-102 treatment in low-grade intermediate-risk non-muscle invasive bladder cancer: An analysis of three clinical trials.
    Urol Pract. 2025 Nov 11:101097UPJ0000000000000917.
    PubMed         Abstract available
    
    

    
    Urologia

63. MICHAEL SN, Makkar A, Nagaraju S, Sood R, et al
    A randomized study comparing outcomes of intravesical Gemcitabine, Mitomycin C (as hyperthermic intravesical chemotherapy-HIVEC) and Bacillus-Calmette Guerin in intermediate and high-risk non-muscle invasive bladder cancer.
    Urologia. 2025 Nov 11:3915603251388204. doi: 10.1177/03915603251388204.
    PubMed         Abstract available
    
    

    
    World J Urol

64. SCILIPOTI P, Zaurito P, Longoni M, de Angelis M, et al
    Impact of timing between neoadjuvant therapy and radical cystectomy on survival in muscle-invasive bladder cancer.
    World J Urol. 2025;43:673.
    PubMed         Abstract available
    
    
65. LI S, Zhang J, Cheng C, Dai Y, et al
    Utility of node-RADS in preoperatively detecting pelvic lymph node metastasis in bladder cancer.
    World J Urol. 2025;43:676.
    PubMed         Abstract available
    
    

    
    Zhonghua Wai Ke Za Zhi

66. CAI LK, Yang X, Tan ZY, Bai RJ, et al
    [Application of NeoVI-RADS scoring in patients with bladder cancer undergoing neoadjuvant therapy].
    Zhonghua Wai Ke Za Zhi. 2025;63:1111-1117.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.